AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00002621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Study NCT01076322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meptin® Swinghaler
Description: Meptin® Swinghaler®~* Ingredient: Procaterol HCL~* Dosage form: 10g/puff~* Dose(s): 10g~* Dosing schedule: 20g (total 20g)
Study NCT01076322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ventolin® MDI
Description: Ventolin® MDI~* Ingredient: Salbutamol sulfate~* Dosage form: 100g/puff~* Dose(s): 100g~* Dosing schedule: 200g (total 200g)
Study NCT03436030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple breathing manuevers during brief echocardiographic imaging
Description: Valsalva, Muller, light mask CPAP, leg raising, hand grip.
Study NCT00245440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 250 mg tablets; 2 tablets once daily (500 mg) for 3 days
Study NCT00245440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telithromycin
Description: 400 mg tablets; 2 tablets once daily (800 mg) for 5 days
Study NCT03175198 — intervention group
Intervention type: DRUG
Intervention: Prazaxa® Capsules
Description: Dosage of Dabigatran etexilate approved in Japan: 300 milligram (mg) daily (150 mg \[as 2 capsules of 75 mg\] twice a day (b.i.d)) or 220 mg (110 mg \[as 1 capsule of 110 mg\] b.i.d) for a treatment duration of 52 weeks.
Study NCT04313790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin Infusion
Description: 500 unit heparin infusion \\ hour for DVT prophylaxis experimental group (n=20)
Study NCT04313790 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: subcutaneous heparin
Description: 5000 unit subcutaneous heparin /8 hours control group n=(20)
Study NCT02201771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT02201771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT02201771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Study NCT02716753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seminal plasma
Study NCT02716753 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Physiological NaCL solution
Study NCT02960126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT02960126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT02437032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Description: Controlled ovarian stimulation with 150-300 UI recombinant FSH
Study NCT02437032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urinary FSH
Description: Controlled ovarian stimulation with 150-300 UI urinary FSH
Study NCT02437032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hMG
Description: Controlled ovarian stimulation with 150-300 UI hMG
Study NCT00189852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chronic heart failure monitoring system
Study NCT00189852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifestyle monitoring system
Study NCT02425722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0456
Description: oral
Study NCT02425722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT04258969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedaling
Description: Participants will pedaling at a low-moderate intensity using a stationary pedal ergometer concurrent to their chemotherapy (FOLFOX or FOLFIRI) infusion. Participants will cycle for 30 min within the first 2 hours of their infusion.
Study NCT00430352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 375mg/m2 iv every 8 weeks
Study NCT03713840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Beverages in Child Care
Description: 12-week intervention promoted consumption of healthy beverages (water, unsweetened low-fat milk) and discouraged consumption of unhealthy beverages (juice, sugar-sweetened beverages, high-fat or sweetened milk). The multi-pronged intervention was delivered via child care centers, targeted children, parents, and child care staff, and included education, environmental changes, and policies.
Study NCT00653302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lantus (insulin glargine) + Glucophage (Metformin)
Study NCT04462523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Study NCT04462523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Prednisolone
Description: Standard of care topical drop treatment
Study NCT02054910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Celiac Plexus Block
Description: Patients will receive celiac plexus block during endoscopy.
Study NCT02054910 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patients will not receive celiac plexus block during endoscopy.
Study NCT02609724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information
Description: During intensive phase: a leaflet with information about the lymphatic system and lymphoedema, clinical evaluation and conservative treatment of lymphoedema During maintenance phase: two informational sessions about self-management and about compression sleeves and other compression material
Study NCT02609724 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Information
Description: During intensive phase: a leaflet with information about the lymphatic system and lymphoedema, clinical evaluation and conservative treatment of lymphoedema During maintenance phase: two informational sessions about self-management and about compression sleeves and other compression material
Study NCT02609724 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information
Description: During intensive phase: a leaflet with information about the lymphatic system and lymphoedema, clinical evaluation and conservative treatment of lymphoedema During maintenance phase: two informational sessions about self-management and about compression sleeves and other compression material
Study NCT02609724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin care
Description: The skin is hydrated during the session. If wounds are present, the wound is cared.
Study NCT02609724 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Skin care
Description: The skin is hydrated during the session. If wounds are present, the wound is cared.
Study NCT02609724 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin care
Description: The skin is hydrated during the session. If wounds are present, the wound is cared.
Study NCT02609724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression therapy
Description: During intensive phase: application of multi-layer, multi-component bandages During maintenance phase: wearing custom-made compression garment
Study NCT02609724 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Compression therapy
Description: During intensive phase: application of multi-layer, multi-component bandages During maintenance phase: wearing custom-made compression garment
Study NCT02609724 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression therapy
Description: During intensive phase: application of multi-layer, multi-component bandages During maintenance phase: wearing custom-made compression garment
Study NCT02609724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided MLD
Description: Fluoroscopy-guided MLD is applied on patient-specific lymphatic system (known from lymphofluoroscopy) by applying cleaning techniques on lymph nodes, resorption techniques to stimulate resorption of lymph by lymph capillaries and gliding technique to stimulate transport of lymph through lymph collectors
Study NCT02609724 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional MLD
Description: Traditional MLD is applied without knowledge of the patient-specific lymphatic architecture. During MLD no cream or oil is used. A pressure with the hands up to 40 mmHg is applied. Drainage is performed at the level of the jugular and occipital region and the belly (in the depth). Draining techniques are applied on the retroclavicular lymph nodes, axillary lymph nodes, humeral lymph nodes and cubital lymph nodes. At the level of the hand, arm, shoulder and trunk, hand movements are applied to stimulate lymphatic transport through the lymph collectors. The therapist's hands perform 'pumping-movements' while stretching the skin.
Study NCT02609724 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MLD
Description: During placebo MLD a superficial massage with massage cream is performed on the patient's contralateral arm and on the belly.
Study NCT02201095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forced air warming
Study NCT02201095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conduction warming mattress
Study NCT02998476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib once daily for 8 weeks followed by once weekly
Study NCT02713438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Planning
Description: CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Each participant forms their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter.
Study NCT02713438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Planning
Description: CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of only one person in the dyad: the child (parent-child dyads).
Study NCT02713438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Planning
Description: CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of both persons within the dyad (parent and child) and include some plans for joint physical activity.
Study NCT02713438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements.~The education is delivered by the experimenter to a parent-child dyad and discusses individual guidelines for both dyadic partners.
Study NCT02713438 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements.~The education is delivered by the experimenter to a parent-child dyad and discusses individual guidelines for both dyadic partners.
Study NCT04303754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes-Specific Formula
Description: Other: Diabetes Specific Formula
Study NCT04303754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread with Spread
Description: Other: White Bread with Spread
Study NCT04303754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice Porridge
Description: Other: Rice Porridge
Study NCT02945371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centered inhibitory control training
Description: A brief, computer-based, multisession training aimed at increasing the connection between environmental risk cues (e.g., cigarettes) and engagement of the brain network for inhibitory control.
Study NCT02945371 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active behavioral response training
Description: A brief computer-based, multisession training aimed at training behavioral responses to personalized environmental risk cues (e.g., cigarettes) that does not engage the inhibitory control network of the brain.
Study NCT00985959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26866138 0.7 mg/m2
Description: JNJ-26866138 0.7 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles.
Study NCT00985959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26866138 1.0 mg/m2
Description: JNJ-26866138 1.0 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles
Study NCT00985959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26866138 1.3 mg/m2
Description: Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.
Study NCT00985959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
Study NCT00985959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
Study NCT03383809 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Strawberry juice with Inulin
Description: Mixture of polyphenols and non digestible carbohydrates
Study NCT03383809 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Strawberry Juice
Description: Source of Polyphenols
Study NCT03383809 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Source of non digestible carbohydrate
Study NCT03331432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid
Description: Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks.
Study NCT03331432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking daily placebo capsules for 4 weeks.
Study NCT01659047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1101
Description: 150 mg taken twice daily by mouth
Study NCT00748488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy aimed to move safely
Description: Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease solely focused on safety of movement.~Duration program: 2 years Maximum number of sessions: 35 per year Duration sessions: 30 minutes
Study NCT00748488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy aimed to improve Physical Activity
Description: Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease combined with a coaching program aimed to promote the level of physical activity Duration program: 2 years Maximum number of sessions: 35 per year Duration of sessions: 30 minutes
Study NCT05091554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraoral ice pack application
Description: Tap water was filled into plastic ice molds and kept in the freezer in the clinic until the application was made. The ice packs used were weighed with digital pocket scale (Knmaster CT1000, Turkey) as 6-8 grams. In the cryotherapy groups, at the end of the first appointment ice packs were removed from the freezer, wrapped in sterile gauze and placed on the vestibular mucosa of the teeth.
Study NCT03579433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORA with VerifEye+
Description: Intraoperative device that measures total corneal astigmatism in the aphakic condition and is used for the selection of IOL power. In the pseudophakic condition, ORA provides guidance for the alignment of the toric axis mark.
Study NCT03579433 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcon Barrett Toric Calculator
Description: Web-based software application that utilizes an algorithm (Barrett Formula) to estimate the amount of post-operative corneal astigmatism in order to optimize IOL model selection and axis placement, with interoperative axis alignment done manually.
Study NCT03579433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acrysof® IQ Toric IOL
Description: Intraocular lens implanted as a replacement for the cataractous lens during cataract surgery (Model SN6AT3, SN6AT4, Model SN6AT5, Model SN6AT6)
Study NCT03579433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acrysof® IQ Toric IOL
Description: Intraocular lens implanted as a replacement for the cataractous lens during cataract surgery (Model SN6AT3, SN6AT4, Model SN6AT5, Model SN6AT6)
Study NCT04041024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tasks and questionnaires
Description: Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer.
Study NCT04041024 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: tasks and questionnaires
Description: Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer.
Study NCT00437619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcipotriol hydrate [Daivonex]
Description: 50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a >50% response to Daivobet from weeks 0-4.
Study NCT04665349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutricia Pre-op, 400 milliliters, per os
Description: After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
Study NCT04355052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine in combination with camostat mesylate
Description: Two drugs which may act as antivirals against SARS CoVid 2 (Hydroxychloroquine may also act as an immunomodulator, Camostat mesylate is a protease inhibitor)
Study NCT04355052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine in combination of Azithromycin
Description: Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
Study NCT02672137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: knowledge translation
Description: knowledge translation that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
Study NCT03083093 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The initial CTPA will be reviewed
Description: The initial CTPA will be reviewed
Study NCT01591655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat
Description: 1 drop of study medication into the study eye four times daily (QID) for 14 days
Study NCT01591655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop of vehicle into the study eye QID for 14 days.